0001209191-22-059242.txt : 20221201 0001209191-22-059242.hdr.sgml : 20221201 20221201183556 ACCESSION NUMBER: 0001209191-22-059242 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221129 FILED AS OF DATE: 20221201 DATE AS OF CHANGE: 20221201 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Onyia Jude CENTRAL INDEX KEY: 0001894425 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 221439887 MAIL ADDRESS: STREET 1: C/O NEUROCRINE BIOSCIENCES, INC. STREET 2: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330525145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-11-29 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001894425 Onyia Jude 12780 EL CAMINO REAL SAN DIEGO CA 0 1 0 0 Chief Scientific Officer Common Stock 2022-11-29 4 S 0 2331 121.9048 D 2366 D Sale of 2,331 shares of common stock issued upon vesting of 4,425 restricted stock units on November 29, 2022 to cover payroll and withholding taxes, with the balance of the shares (2,094) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $121.18 to $122.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Includes an aggregate of 272 shares purchased on August 31, 2022 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. /s/ Darin Lippoldt, Attorney-in-Fact 2022-12-01